Gossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.05 better than the analyst estimate of ($0.85).

“We are very excited about the continued advancement of our pipeline with the start of two robust Phase 2 clinical trials for GB002 and GB004 and the planned dose expansion cohort for GB1275,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We believe that these clinical programs hold tremendous potential to benefit high unmet need patient populations.”

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.